Tuesday, July 1, 2025 7/1/2025

Tailored siRNA delivery to human endothelium to inhibit and reverse inflammatory damage following ischemia reperfusion injury in the kidney

Award Number: R00HL157552
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2025

Group Awards By:

View Award Description

Tailored siRNA delivery to human endothelium to inhibit and reverse inflammatory damage following ischemia reperfusion injury in the kidney - Abstract Ischemia reperfusion injury (IRI) causes endothelial inflammation and microvascular rarefaction that leads to adverse kidney graft outcomes in organ transplant. Direct treatment of endothelial cells (EC) can reduce the impact of IRI on the health of the graft, but there is a lack of EC targeted therapies that can effectively intervene and alleviate the various modes of dysfunctional endothelial response. The goal of this work is to develop a therapeutic strategy that addresses the two key modes of endothelial damage in response to IRI: dysfunctional inflammation in ECs and damage to capillary networks, in a site-specific and temporary manner. We propose that therapeutic siRNA can be delivered directly to endothelial cells using polymeric nanoparticles (NPs), which provide a customizable platform to enhance the cell penetration and to sustain the delivery of nucleic acids. In Aim 1, we will determine the NP characteristics utilizing a novel family of PACE polymers that enable maximum and sustained siRNA to endothelial cells in order to reduce adhesion molecule expression upon inflammatory activation. In Aim 2, we will translate this knowledge of structure/function relationship of the NP to rationally design siRNA-mediated knockdown of adhesion molecules in relevant models of 3D human vasculature and evaluate the long-term effect after transplantation in vivo. In the R00 phase of the award, the principles determined in Aim 1 and 2 to impact endothelial-NP interaction will be applied to polymer NPs delivered within a hydrogel delivery vehicle to the renal cortex. Aim 3 will investigate the potential of endothelial-tailored siRNA-NPs to locally deliver anti-fibrotic siRNAs within an ECM-derived hydrogel to IRI- damaged renal cortex in vivo. Dr. Laura Bracaglia has earned her PhD in Bioengineering and began this investigation as a postdoctoral fellow in the Department of Biomedical Engineering at Yale University. In her training so far, she has studied NP and drug delivery methods in human tissue models that provide translatable insights into vascular inflammation. During the first year of this fellowship, she acquired additional training in the 1) chemical and polymer science aspects involved in the development of NPs, 2) vascular immune biology, 3) renal pathology and response to injury, and 4) translation to human immunology. With newly gained expertise in these key areas, Laura has continued this investigation as an independent investigator in her new role as Assistant Professor at Villanova University.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $303,709 )
2024	2024	VILLANOVA UNIVERSITY IN THE STATE OF PENNSYLVANIA	800 E LANCASTER AVE	VILLANOVA	PA	19085	DELAWARE	USA	Cardiovascular Diseases Research	001	5	8/30/2024	SUPPLEMENT FOR EXPANSION	$58,434
2024	2024	VILLANOVA UNIVERSITY IN THE STATE OF PENNSYLVANIA	800 E LANCASTER AVE	VILLANOVA	PA	19085	DELAWARE	USA	Cardiovascular Diseases Research	000	5	8/16/2024	NON-COMPETING CONTINUATION	$245,275
														Subtotal = $303,709

Issue Date FY: 2023 ( Subtotal = $336,422 )
2023	2023	VILLANOVA UNIVERSITY IN THE STATE OF PENNSYLVANIA	800 LANCASTER AVE	VILLANOVA	PA	19085	DELAWARE	USA	Cardiovascular Diseases Research	001	4	8/16/2023	NON-COMPETING CONTINUATION	$247,775
2023	2022	VILLANOVA UNIVERSITY IN THE STATE OF PENNSYLVANIA	800 LANCASTER AVE	VILLANOVA	PA	19085	DELAWARE	USA	Cardiovascular Diseases Research	000	3	12/1/2022	EXTENSION WITH OR WITHOUT FUNDS	$0
2023	2022	VILLANOVA UNIVERSITY IN THE STATE OF PENNSYLVANIA	800 LANCASTER AVE	VILLANOVA	PA	19085	DELAWARE	USA	Cardiovascular Diseases Research	002	3	8/21/2023	EXTENSION WITH OR WITHOUT FUNDS	$88,647
														Subtotal = $336,422

Issue Date FY: 2022 ( Subtotal = $249,000 )
2022	2022	VILLANOVA UNIVERSITY IN THE STATE OF PENNSYLVANIA	800 LANCASTER AVE	VILLANOVA	PA	19085	DELAWARE	USA	Cardiovascular Diseases Research	000	3	8/18/2022	EXTENSION WITH OR WITHOUT FUNDS	$249,000
														Subtotal = $249,000

Grand Total All Awards = $889,131

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Tailored siRNA delivery to human endothelium to inhibit and reverse inflammatory damage following ischemia reperfusion injury in the kidney

Award Number: R00HL157552

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer